Veracyte (FRA:12V) YoY EBITDA Growth : -839.02% (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Veracyte YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Veracyte's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was -839.02%.

Veracyte's EBITDA per Share for the three months ended in Dec. 2023 was €-0.30.

Veracyte YoY EBITDA Growth Historical Data

The historical data trend for Veracyte's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veracyte YoY EBITDA Growth Chart

Veracyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

62.56

-171.71

-95.16

83.13

-358.82

Veracyte Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
YoY EBITDA Growth	Get a 7-Day Free Trial															168.33	82.00	56.10	-725.71	-839.02

Veracyte YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Veracyte's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(-0.624	-	-0.136)	/	\| -0.136 \|
=	-358.82 %

Veracyte's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (Q: Dec. 2023 )
=	(EBITDA per Share (Q: Dec. 2023 )	-	EBITDA per Share (Q: Dec. 2022 ))	/	\| EBITDA per Share (Q: Dec. 2022 )) \|
=	(-0.303	-	0.041)	/	\| 0.041 \|
=	-839.02 %

Veracyte YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Veracyte's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Veracyte (FRA:12V) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Veracyte Inc (FRA:12V) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

VCYT:USA

Address

6000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.veracyte.com

Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. The company derives its revenues from the Sale of Afirma analysis products.

Veracyte (FRA:12V) Headlines

No Headlines